In JIA, the S100 calcium-binding alarmin proteins (S100A8, S100A9, and S100A12) have been identified as biomarkers for risk of flare upon withdrawal of methotrexate therapy and for identifying individuals less likely to respond to T cell targeting agents (27, 39–41). Here, S100A9 is linked to juvenile idiopathic arthritis.